Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Clinical Trial to Evaluate the Effects of Broc Shot Capsules on Skin Appearance and Comfort in Adults With Reactive, Blemish-Prone, or Hormonally Affected Skin

12. November 2026 aktualisiert von: BrocShot Inc

This is a randomized, double-blind, placebo-controlled, fully decentralized (remote) clinical trial evaluating the effects of Broc Shot Capsules on skin appearance and comfort in adults with reactive, blemish-prone, or hormonally affected skin. Fifty participants aged 18-65 years will be randomly assigned in a 1:1 ratio to receive either Broc Shot Capsules (active) or matched placebo capsules for 8 weeks.

Participants will take 2 capsules once daily and complete self-reported questionnaires and standardized self-captured skin photographs at Baseline, Week 4, and Week 8 via a secure online study platform. Expert dermatologist grading of photographs will be conducted remotely at each timepoint. The study is designed to substantiate consumer product claims related to visible skin improvement and participant-reported skin comfort, and is not intended to evaluate treatment of any clinical dermatological disease.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

50

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adults aged 18 to 65 years (inclusive) at the time of consent.
  • Self-reported skin concerns matching at least one of the following descriptions: I have red, itchy skin patches
  • I have dry, flaky/scaley skin patches
  • my skin has blemishes such as pimples, discoloured papules (small, tender bumps that are pink/red/purple/or darker than your natural skin tone) or pustules (a distinct white or yellow pus-filled center surrounded by a red base).
  • Generally healthy adults who are willing and able to follow the study protocol for the full 8-week duration, including taking 2 capsules of the study product once daily for 8 consecutive weeks without skipping days, answering questionnaires at Baseline, Week 4, and Week 8, and following the photograph submission protocol at Baseline, Week 4, and Week 8.
  • Willing to avoid initiating any new topical or oral skincare products, prescription medications targeting skin, or other dietary supplements specifically marketed for skin benefit during the study period.
  • Participants currently using such products who have been using them consistently for at least 3 months prior to enrollment and are willing to continue unchanged throughout the study are eligible.
  • Willing to maintain their current diet, lifestyle, sleep pattern, sun exposure habits, and skincare routine for the duration of the trial.
  • Resides within the United States.
  • Access to a smartphone or computer with internet connection and the ability to use the Citruslabs digital study platform.

Exclusion Criteria:

  • Known allergy, hypersensitivity, or intolerance to broccoli, horseradish, other cruciferous vegetables (Brassicaceae family), or any component of the study product or placebo capsule.
  • Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
  • Currently taking prescription anticoagulant medications (e.g., warfarin, apixaban, rivaroxaban) due to the potential for product ingredients to interact with anticoagulant activity.
  • History of a severe or unstable medical condition that, in the opinion of the study team, would prevent safe participation or adherence to the protocol, including active cancer treatment.
  • Currently using any oral, topical, or biologic prescription medication specifically indicated for a diagnosed dermatological condition, unless the regimen has been stable for at least 3 months and no changes are planned during the study period.
  • Planned dermatological procedures during the study period (e.g., chemical peels, laser treatments, microneedling, injectable cosmetic procedures) that could confound skin appearance assessments.
  • Currently enrolled in another clinical or consumer research study, or plans to enroll in any such study during the 8-week study period.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Placebo-Komparator

Participants will take 2 capsules once daily, with their first meal of the day, avoiding administration with hot or acidic liquids.

Experimental: BrocShot Collagen

Participants will take 2 capsules once daily, with their first meal of the day, avoiding administration with hot or acidic liquids.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Clinician-Assessed Change in Overall Skin Appearance
Zeitfenster: Baseline to Week 8

Change from Baseline in overall skin appearance graded by a qualified dermatologist reviewing participant-submitted digital photographs using a binary Yes/No improvement scale assessing overall skin health, pigmentation, dryness, brightness, scarring, blemishes, redness, and flaking

Baseline to Week 8

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Participant-Reported Change in Skin Appearance
Zeitfenster: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin appearance assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Clarity
Zeitfenster: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin clarity assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Calmness
Zeitfenster: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin calmness assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Visible Skin Concerns
Zeitfenster: Baseline, Week 4, and Week 8

Change from Baseline in self-reported visible skin concerns assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Texture
Zeitfenster: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin texture assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Luminosity
Zeitfenster: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin luminosity assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Age Appearance
Zeitfenster: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin age appearance assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Itching and Irritation
Zeitfenster: Baseline, Week 4, and Week 8

Change from Baseline in self-reported itching and irritation assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Comfort
Zeitfenster: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin comfort assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Confidence
Zeitfenster: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin confidence assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. November 2026

Primärer Abschluss (Geschätzt)

1. Januar 2027

Studienabschluss (Geschätzt)

1. Januar 2027

Studienanmeldedaten

Zuerst eingereicht

12. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren